248 related articles for article (PubMed ID: 26993207)
1. Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.
Murakami R; Matsumura N; Mandai M; Yoshihara K; Tanabe H; Nakai H; Yamanoi K; Abiko K; Yoshioka Y; Hamanishi J; Yamaguchi K; Baba T; Koshiyama M; Enomoto T; Okamoto A; Murphy SK; Mori S; Mikami Y; Minamiguchi S; Konishi I
Am J Pathol; 2016 May; 186(5):1103-13. PubMed ID: 26993207
[TBL] [Abstract][Full Text] [Related]
2. The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1).
Murakami R; Matsumura N; Michimae H; Tanabe H; Yunokawa M; Iwase H; Sasagawa M; Nakamura T; Tokuyama O; Takano M; Sugiyama T; Sawasaki T; Isonishi S; Takehara K; Nakai H; Okamoto A; Mandai M; Konishi I
Gynecol Oncol; 2019 May; 153(2):312-319. PubMed ID: 30853361
[TBL] [Abstract][Full Text] [Related]
3. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
[TBL] [Abstract][Full Text] [Related]
4. Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.
Ohsuga T; Yamaguchi K; Kido A; Murakami R; Abiko K; Hamanishi J; Kondoh E; Baba T; Konishi I; Matsumura N
BMC Cancer; 2017 Aug; 17(1):580. PubMed ID: 28851311
[TBL] [Abstract][Full Text] [Related]
5. Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.
Wang C; Armasu SM; Kalli KR; Maurer MJ; Heinzen EP; Keeney GL; Cliby WA; Oberg AL; Kaufmann SH; Goode EL
Clin Cancer Res; 2017 Aug; 23(15):4077-4085. PubMed ID: 28280090
[No Abstract] [Full Text] [Related]
6. Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles.
Murakami R; Matsumura N; Brown JB; Wang Z; Yamaguchi K; Abiko K; Yoshioka Y; Hamanishi J; Baba T; Koshiyama M; Mandai M; Yamada R; Konishi I
Gynecol Oncol; 2016 Apr; 141(1):49-56. PubMed ID: 27016229
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.
Konecny GE; Wang C; Hamidi H; Winterhoff B; Kalli KR; Dering J; Ginther C; Chen HW; Dowdy S; Cliby W; Gostout B; Podratz KC; Keeney G; Wang HJ; Hartmann LC; Slamon DJ; Goode EL
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25269487
[TBL] [Abstract][Full Text] [Related]
8. Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer.
Zhang S; Jing Y; Zhang M; Zhang Z; Ma P; Peng H; Shi K; Gao WQ; Zhuang G
Sci Rep; 2015 Nov; 5():16066. PubMed ID: 26530441
[TBL] [Abstract][Full Text] [Related]
9. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
[TBL] [Abstract][Full Text] [Related]
10. Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study.
Vargas HA; Miccò M; Hong SI; Goldman DA; Dao F; Weigelt B; Soslow RA; Hricak H; Levine DA; Sala E
Radiology; 2015 Mar; 274(3):742-51. PubMed ID: 25383459
[TBL] [Abstract][Full Text] [Related]
11. Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.
Torres D; Wang C; Kumar A; Bakkum-Gamez JN; Weaver AL; McGree ME; Konecny GE; Goode EL; Cliby WA
Gynecol Oncol; 2018 Aug; 150(2):227-232. PubMed ID: 29925470
[TBL] [Abstract][Full Text] [Related]
12. Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
Zhang Q; Wang C; Cliby WA
Gynecol Oncol; 2019 Feb; 152(2):368-374. PubMed ID: 30448260
[TBL] [Abstract][Full Text] [Related]
13. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
14. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A
J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210
[TBL] [Abstract][Full Text] [Related]
15. Subtyping of high grade serous ovarian carcinoma: histopathological and immunohistochemical approach.
Khashaba M; Fawzy M; Abdel-Aziz A; Eladawei G; Nagib R
J Egypt Natl Canc Inst; 2022 Feb; 34(1):6. PubMed ID: 35138498
[TBL] [Abstract][Full Text] [Related]
16. Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Chen J; Shi X; Xiao L; Li Z; Li Z; Sun L
Cancer Med; 2022 Oct; 11(20):3761-3770. PubMed ID: 35434908
[TBL] [Abstract][Full Text] [Related]
17. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
[TBL] [Abstract][Full Text] [Related]
18. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the prognostic potential of histopathological subtyping in high-grade serous ovarian carcinoma.
Zelisse HS; Hwan RA; van de Vijver MJ; Dijk F; Mom CH; Hooijer GKJ; van Gent MDJM; Snijders MLH
Virchows Arch; 2024 Apr; ():. PubMed ID: 38622323
[TBL] [Abstract][Full Text] [Related]
20. Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
Zeng H; Chen L; Zhang M; Luo Y; Ma X
Gynecol Oncol; 2021 Oct; 163(1):171-180. PubMed ID: 34275655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
